High Throughput Screening Market: Comprehensive Research Including Top Companies and Forecasts Report 2017-2023

Growth of the HTS market include initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological improvements in HTS, and the availability of government funding and venture capital investments. The base year considered for the study is 2017 and the forecast period includes 2018 to 2023. However, the overall use and adoption of HTS and associated instruments face challenges in the form of a dearth of skilled operators to use them and the costly and time-consuming nature of HTS techniques.

The high-throughput screening market was valued at USD 13.87 Billion in 2017 and is expected to reach USD 21.69 Billion in 2023, at a CAGR of 7.8% during the forecast period.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950&utm_source=openpr-7-2-20&utm_medium=Openpr

On the basis of products & services, the high-throughput screening market is segmented into instruments, reagents & assay kits, consumables & accessories, software, and services. Of all these segments, reagents and assay kits accounted for the largest share of the HTS market in 2017. The large share of this market segment can primarily be attributed to factors such as the large numbers of reagents and assay kits used in HTS techniques, rising prevalence of a number of diseases, increasing pharmaceutical R&D, and increased government funding for life science research.

The software segment, on the other hand, is expected to be the fastest-growing segment of the HTS market. Market growth can largely be attributed to the increasing automation of high-throughput screening and the availability of data management software tools, which enable researchers to develop systematic and process-oriented approaches toward HTS techniques.

Pharmaceutical and biotechnology companies to dominate the market share

The global high-throughput screening market is categorized into four major end-user segments, namely, pharmaceutical and biotechnology companies, academic and government institutes, contract research organizations (CROs), and other end users (hospitals and food, agriculture, & environmental industries). In 2017, the pharmaceutical and biotechnology companies segment accounted for the largest share of the global HTS market. The large share of this segment is primarily attributed to the extensive use of the HTS technology in pharmaceutical and biotechnology companies for drug discovery applications along with the increasing pharmaceutical R&D expenditure.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=134981950&utm_source=openpr-7-2-20&utm_medium=Openpr

Geographical Region Covered

North America to account for the largest market size during the forecast period.

North America is the largest market for high-throughput screening, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In addition, this region has shown strong commercialization of pharmaceutical and biotechnology research. The generic manufacturers need HTS platforms for hit identification and target validation in drug discovery and development. According to the US Food and Drug Administration (FDA), the total number of generic drug approvals in 2014 was 409, which increased to 763 in 2017. The increased focus on generic medicines is also expected to aid the growth of the HTS market in this region.

Leading Companies

Agilent (US), Danaher (US), Thermo Fisher Scientific (US), PerkinElmer (US), Tecan Group (Switzerland), Axxam (Italy), Merck Group (Germany), Bio-Rad (US), Hamilton Company (US), Corning Incorporated (US), BioTek Instruments (US), and Aurora Biomed (Canada).

Contact Us:
Mr. Shelly Singh
MarketsandMarkets(TM) INC.
630 Dundee Road
Suite 430
Northbrook, IL�60062
USA: +1-888-600-6441
Email:�sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com

About MarketsandMarkets(TM)
MarketsandMarkets(TM) provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets(TM) for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets(TM) are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets(TM) now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets(TM) is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.